Centre Hospitalier Intercommunal De Frejus-Saint-Raphaeel
- Address
- 240 Avenue De Saint Lambert, 83600 Fréjus, France
Centre Hospitalier Intercommunal De Frejus-Saint-Raphaeel
The Centre Hospitalier Intercommunal De Frejus-Saint-Raphaeel is a comprehensive medical research facility conducting pivotal clinical trials across multiple therapeutic areas. The center demonstrates particular strength in oncology research, with extensive expertise in breast cancer therapeutics and gastrointestinal malignancies, while also maintaining active programs in critical care, infectious diseases, and dermatology.
- Advanced breast cancer treatment strategies, including personalized medicine approaches using circulating tumor DNA (ctDNA) monitoring and hormone receptor-positive disease management
- Gastrointestinal oncology research, focusing on pancreatic adenocarcinoma and colon carcinoma with innovative chemotherapy regimens and adjuvant treatment optimization
- Infectious disease therapeutics, particularly in sexually transmitted infections and HPV-related conditions
- Critical care medicine, including metabolic emergency management and intensive care protocols for diabetic ketoacidosis
The center's oncology program stands out for its commitment to precision medicine, implementing cutting-edge technologies such as gene expression profiling and ctDNA testing to guide treatment decisions. Their breast cancer research portfolio includes multiple phase III trials evaluating therapeutic de-escalation strategies and targeted therapies, aiming to optimize outcomes while minimizing treatment burden for patients. The facility also contributes to national and international collaborative networks, participating in large-scale PRODIGE trials for colorectal cancer management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Intercommunal De Frejus-Saint-Raphaeel
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing Sodium Chloride and Sodium Lactate in the Management of Severe Diabetic Ketoacidosis in ICU Patients | Centre Hospitalier Universitaire De Nice | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 4 | Unknown | 2017-03-22 | 2026-04-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.